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Lung cancer is the leading cause of cancer-related mortality in both men and women and approximately 219,440 new cases of
nonsmallcelllungcancer(NSCLC)wereestimatedtooccurintheUSAin2009,whichcaused159,390NSCLC-relateddeaths.More
than 50% of cases of advanced NSCLC are diagnosed in patients older than age 65, and recent Surveillance Epidemiology and End
Results (SEERs) data suggest that the median age at diagnosis is 70 years. Until recently, the disease has been undertreated in this
patient population, with a perception among many clinicians that elderly patients do not tolerate chemotherapy or radiotherapy.
So, single agent chemotherapy is the recommended approach by the ASCO and International Expert Panels in unselected patients.
Theintroductionofnoveltargetedtherapies,suchasEpidermalGrowthFactorReceptor(EGFR)TyrosineKinaseInhibitors(TKIs)
which improved survival versus placebo in patients who had previously failed on chemotherapy, gives clinicians new, eﬀective, and
better tolerated options to consider when treating NSCLC in elderly patients. This paper describes the advances of EGFR TKIs for
elderly patients with advanced NSCLC.
1.Introduction
Lung Cancer is the most common cancer in the world
and the leading cause of cancer-related deaths in Western
countries [1]. NSCLC constitutes between 80% and 85%
of all lung cancers. The median age at diagnosis is now
70 years [2] and most patients with NSCLC have incurable
diseaseatdiagnosis,withonlyapproximately15%presenting
with localized disease [3]. Treatment for advanced disease
is palliative in nature. In patients with a good performance
status (PS), ﬁrst-line treatment with platinum-based com-
bination chemotherapy leads to improved overall survival
(OS) and improvement in symptoms [4–6]. However, in
elderly patients, single-agent chemotherapy with a third-
generation agent (vinorelbine, gemcitabine, or taxanes) is
the recommended approach by the American Society of
Clinical Oncology guidelines and international expert panels
in unselected patients [7, 8]. Moreover, in current practice,
the elderly are often excluded from participation in clinical
trials and receive empirical or inadequate treatment [9].
Retrospective analyses of trials not restricted to elderly
patients have generally demonstrated that the elderly have
similar response rates (RRs) to chemotherapy as younger
patients and also similar survival beneﬁts. Most studies
also have shown that older patients are more likely to
stop treatment as a result of toxicity, although, objectively,
these studies have reported either little or no increase in
toxicity in elderly subgroup [8, 10–16]. Availability of an
eﬀective, less toxic therapy might help extend potentially
beneﬁcial treatment to a greater proportion of older patients
with advanced NSCLC and TKIs represent just these kinds
of drugs. The EGFR family is part of a complex signal-
transductionnetworkthatiscentraltoseveralcriticalcellular
processes. The EGFR (also known as ErbB-1/HER1) is a
170-kDa transmembrane glycoprotein that consists of an
extracellular domain that recognizes and binds to speciﬁc
ligands, a hydrophobic transmembrane domain, which is
involvedininteractionsbetweentworeceptorswithinthecell
membrane, and an intracellular domain that contains the
tyrosine kinase enzymatic activity. Since EGFR expression
is often found in NSCLC cells [17, 18], it has been the
focus of eﬀorts to develop new agents that target the2 Current Gerontology and Geriatrics Research
EGFR pathway. Erlotinib and geﬁtinib inhibit the tyrosine
kinase activity of EGFR and have been studied extensively
[19–22]. Besides the two rather selective TKIs of EGFR,
other TKIs with a broader spectrum of activity and other
Monoclonal Antibodies (MoAb) to extracellular domain
of the EGFR are also being tested in advanced NSCLC.
Among broader spectrum EGFR TKIs are lapatinib, which
are also active against ErbB2/neu, another member of the
EGFR family of receptors, and vandetanib, which inhibits
theVascularEndotelialGrowthFactor(VEGF)receptor[23].
However,lapatinibisapprovedforthetreatmentofadvanced
breast cancer and the development of vandetanib has been
discontinued by AstraZeneca in 2010.
2.Geﬁtinib
Geﬁtinib (ZD1839) is an orally available EGFR small-
molecule TKI. In two large phase II trials, IDEAL 1 and
2, geﬁtinib monotherapy was demonstrated to be active
and well tolerated in advanced NSCLC patients which
progressed after one or more chemotherapy regimens
[20, 21]. These trials led to US FDA approval of geﬁtinib
as salvage third-line therapy for NSCLC in May 2003, as
a single agent after failure of both platinum-based and
docetaxel chemotherapies. Geﬁtinib activity as a single
agent at a dose of 250mg was not conﬁrmed in a placebo
controlled randomized phase III Iressa Survival Evaluation
in Lung Cancer (ISEL) trial in advanced NSCLC with heavily
pretreated patients [24]. However, preplanned subgroup
analyses indicated statistically diﬀerent survival beneﬁt in
never smokers and in patients of Eastern Asian origin. In
June 2005, on the basis of the lack of survival beneﬁt in the
ISEL study, the FDA restricted the use of geﬁtinib to patients
participating in a clinical trial or who were continuing to
beneﬁt from treatment already initiated [25]. Currently,
geﬁtinib is marketed in several countries in eastern Asia and
in the late 2009 was approved by EMEA for the treatment
of locally advanced or metastatic NSCLC patients who have
been pretreated with platinum-based chemotherapy.
Two further studies retrospectively analyzed geﬁtinib in
previously treated elderly patients with advanced NSCLC
and reported a response rate of 0% and 5%, respectively.
However, in the Cappuzzo et al. study, the stable disease rate
was 45% [26, 27].
Recently, the INTEREST-randomized phase III trial in
previouslytreatedNSCLCestablishednoninferiorsurvivalof
geﬁtinib compared with docetaxel (7.6 versus 8.0 months,
resp.), suggesting that geﬁtinib is a valid treatment for
pretreated patients with advanced NSCLC. Superiority of
geﬁtinib in patients with high EGFR-gene-copy number was
not proven [28]. In our knowledge, the only published
paper on geﬁtinib as ﬁrst-line treatment and elderly patients
with advanced NSCLC was published by Crin` o et al. [29].
They performed a randomized phase II study (INVITE)
of geﬁtinib versus vinorelbine in 196 chemotherapy-na¨ ıve
unselected elderly patients (age ≥70 years). Patients enrolled
in this study reﬂected a European population seen in clinical
practice, because the vast majority of patients were male
(77%), were smokers (82%), and had squamous cell carci-
noma (48%). The primary end point was progression-free
survival (PFS). Secondary end points were overall survival
(OS), objective response rate (ORR), quality of life (QoL),
pulmonary symptom improvement (PSI), and tolerability.
This study showed no statistical diﬀerence between geﬁtinib
and vinorelbine in terms of PFS (2.7 versus 2.9 months, resp.
P = .310), OS (5.9 versus 8.0 months, resp.), ORR (3.1%
versus 5.1%, resp.), and disease control rates (43.3% versus
53.5%, resp.); however, the toxicity proﬁle and overall QoL
assessments favored geﬁtinib. Drug-related serious adverse
events (AEs) were less frequent in the geﬁtinib arm versus
vinorelbinearm(12.8%versus41.7%,resp.).Patientstreated
with geﬁtinib had a numerically lower incidence of fatigue
and gastrointestinal AEs, notably constipation, which is an
important side eﬀect in the elderly population and also
hematologic toxicity was conﬁned to patients treated with
vinorelbine. Most patients were analyzed for EGFR gene
copy number by FISH, and surprisingly, those who were
EGFR FISH-positive and who received geﬁtinib appeared to
have poorer outcomes than those who were EGFR FISH-
negative and who received geﬁtinib. In the small subgroup of
EGFR FISH-positive patients, those treated with vinorelbine
achievednonsigniﬁcantbetterPFSandOSthanthosetreated
with geﬁtinib. A clear explanation for the discrepancy in
FISH result is not currently evident, but it could be useful
to perform EGFR as well K-RAS mutation analyses in this
patient population. Unfortunately, in INVITE trial there
weretoofewpatientsintheK-RASmutationanalysistodraw
any accurate conclusions [29]( Table 1).
The ﬁrst-line geﬁtinib versus carboplatin/paclitaxel
(Iressa Pan-Asia Study (IPASS) study was a phase III
study in clinically selected patients in East Asia who had
advanced NSCLC. The primary end point was PFS and
evaluations of eﬃcacy according to the baseline biomarker
status of EGFR were planned exploratory objectives. There
was a signiﬁcant interaction between treatment and EGFR
mutation with respect to PFS (P<. 001). PFS was
signiﬁcantly longer among patients receiving geﬁtinib than
that among those receiving carboplatin-paclitaxel in the
mutation-positive subgroup (P<. 001) and signiﬁcantly
shorter among patients receiving geﬁtinib than that among
receiving carboplatin-paclitaxel in the mutation-negative
subgroup (P<. 001). The ORR in the overall population was
signiﬁcantlyhigherwithgeﬁtinibthanthatwithcarboplatin-
paclitaxel (43% versus 32.2%, resp.; P<. 001). The ORR
was 71.2% with geﬁtinib versus 47.3% with carboplatin-
paclitaxel in the mutation-positive subgroup (P<. 001) and
1.1% versus 23.5%, respectively, in the mutation-negative
subgroup (P = .001). Signiﬁcantly more patients in the
geﬁtinib group than in the carboplatin-paclitaxel group had
a clinically relevant improvement in quality of life (P<
.001). Interstizial lung disease (ILD) events occurred in
2.6% patients treated with geﬁtinib and in 1.4% patients
treated with carboplatin-paclitaxel. The Authors concluded
that geﬁtinib is superior to carboplatin-paclitaxel as an
initial treatment for pulmonary adenocarcinoma among
nonsmokers or former light smokers in East Asia. The
presence in the tumor of a mutation of the EGFR gene isCurrent Gerontology and Geriatrics Research 3
Table 1: Main studies on EGFR TKIs for elderly (≥70 years)
patients with advanced NSCLC.
Author Study arm No. of
patients
Response
rate (%)
Median OS
(months)
Shepherd∗
et al. [31]
Erlotinib
versus 112 8 7.6
Placebo 50 0 5.0
Wheatley-
Price§ et al.
[32]
Erlotinib 80 10 10.9
Crin` o§ et al.
[29]
Geﬁtinib
versus 99 3.1 5.9
Vinorelbine 97 5.1 8.0
∗2nd or 3rd -line; §ﬁrst -line.
a strong predictor of a better outcome with geﬁtinib. This
study was not targeted for elderly NSCLC patients (median
age of enrolled patients was 57 years); however it showed
that patients in whom an EGFR mutation has been identiﬁed
will beneﬁt most from ﬁrst-line therapy with geﬁtinib
[30].
3.Erlotinib
Erlotinib in a phase III, randomized, placebo-controlled trial
(BR.21 study) has been proven to prolong survival compared
with best supportive care (6.7 months versus 4.7 months
for erlotinib and for placebo, resp.) in unselected NSCLC
patients after ﬁrst- or second-line chemotherapy failure [31].
Based on the results of this trial, erlotinib was approved by
the US FDA in November 2004 and by the EMEA in October
2005 for the treatment of chemotherapy-resistant advanced
NSCLC patients. However, the mild safety proﬁle of erlotinib
makes it particularly suitable to be tested prospectively as a
single agent in the ﬁrst-line treatment of elderly patients as
an alternative to cytotoxic chemotherapy.
Wheatley-Price et al. performed a retrospective analysis
of elderly subgroup enrolled in BR.21 study and demon-
strated that elderly patients treated with erlotinib gain
similar survival and QoL beneﬁts as younger counterpart
but experience greater toxicity. At study entry, 162 patients
(22%) were pretreated elderly (112 randomly assigned to
erlotinib). Eight percent of elderly erlotinib patients had an
objective response, and 70% had a best response of stable
disease compared with 9% and 59% of young patients,
but these diﬀerences were not signiﬁcant. No signiﬁcant
diﬀerences were seen in median duration of response (39
weeks versus 34 weeks, resp.) and in survival beneﬁt between
elderly and young patients (3.0 months versus 2.1 months,
resp.). Thirty-ﬁve % of the elderly group experienced severe
toxicity (grade ≥3) compared with 18% of the younger
group (P<. 001). The elderly were more likely than the
youngergrouptohavegrade ≥3rash,fatigue,stomatitis,and
dehydration, as well as any grade of anorexia and fatigue.
Fatal drug-related toxicities were unusual and occurred in
only ﬁve patients (two young and three elderly patients).
When we consider dyspnea, cough, and pain, QoL beneﬁts
were similar in elderly and young patients [32]( Table 1).
A recent phase II study by Jackman et al. reported the
eﬃcacy of erlotinib as ﬁrst-line treatment in 80 unselected
patients greater than 70 years of age with stage IIIB or IV
NSCLC. There were eight partial responses and thirty-three
stable diseases for an overall disease control rate of 51%. The
most frequent AEs were rash (79%) and diarrhea (69%).
In general, toxicities were mild and easily managed. Fifteen
patients experienced treatment-related toxicities ≥grade 3.
Twelve patients were removed from the protocol because
of erlotinib-related toxicity (three patients with ILD, three
with dehydration, three with diarrhea, one with hemoptysis,
one with rash, and one with anorexia). There were four
patientswithpossibleILD,withonetreatment-relateddeath.
Median time to progression (TTP) was 3.5 months and
median survival time was 10.9 months. The 1- and 2-year
survival rates were 46% and 19%, respectively. Treatment-
related rash was correlated with prolonged TTP and survival,
while smoking history and weight loss at presentation
were predictors of shorter survival. The presence of an
EGFR mutation was strongly correlated with disease control,
prolonged TTP (P<. 017) and survival (P<. 027). Not
surprisingly, patients with a KRAS mutation had no clinical
responses and a median TTP of only 2.5 months. Finally,
tumor histology (64% of patients had adenocarcinoma)
was not associated with improved survival in this trial
[33]( Table 1). Hesketh et al. published the results of
phase II study that evaluated the eﬃcacy and tolerability
of single-agent erlotinib in 81 unselected chemotherapy-
na¨ ıve patients with advanced NSCLC and a PS of 2. The
median age of enrolled patients was 74 years. The overall
control disease rate was 42% and the median survival of
5 months is comparable with that reported in prior trials
employing chemotherapy alone in the PS 2 population
[34–38]. This SWOG trial demonstrated that single-agent
erlotinib resulted in an acceptable but signiﬁcant level of
treatment-related side eﬀects for a substantial minority of
chemotherapy-naive patients with advanced NSCLC and PS
2. Moreover, erlotinib does not oﬀer a signiﬁcant treatment
advance over chemotherapy in unselected PS 2 patients [38].
Lilenbaum et al. conﬁrmed that unselected patients with
advancedNSCLCandPS2arebesttreatedwithcombination
chemotherapy as ﬁrst-line therapy. However, erlotinib may
be considered in patients selected by clinical or molecular
markers [37].
A new paradigm of utilizing TKIs is as maintenance drug
after ﬁrst-line treatment obtaining control disease as recently
showen in SATURN and ATLAS studies. The SATURN trial
investigatedtheroleofmaintenancetherapywitherlotinibin
EGFRIHC-positivepatients.Erlotinibsigniﬁcantlyincreased
PFS (P = .000003) and overall survival from 11 months to
12 months compared with placebo [39]. In ATLAS trial, an
improvement in PFS was obtained with the combination of
erlotinib and bevacizumab versus bevacizumab and placebo
as a maintenance therapy [40]. Moreover, in TORCH trial,
Gridelli et al. are investigating whether erlotinib as ﬁrst-
line therapy until progression followed by chemotherapy
with cisplatin/gemcitabine will not be inferior in terms4 Current Gerontology and Geriatrics Research
of survival to the standard arm, consisting of ﬁrst-line
cisplatin/gemcitabine for 6 cycles, followed at progression by
erlotinib until second progression [41].
4.Clinicaland MolecularPredictorsfor
Response to EGFRTKIs
Clinical data suggest that EGFR TKIs geﬁtinib and erlotinib
a r em o r ea c t i v ei nc e r t a i nN S C L Ch i s t o t y p e s ,s u c ha s
in adenocarcinomas and bronchioloalveolar carcinomas
(BAC), in women, in never smokers and in Asian ethnicity
patients [30, 31, 42–46]. However, in BR.21 trial, survival
was signiﬁcantly improved in all subgroups of patients
receiving erlotinib versus placebo, such as male smokers
with squamous cell carcinoma [31]. A subgroup analysis
of the TRIBUTE trial showed that the addition of erlotinib
to paclitaxel/carboplatin prolonged survival in patients who
never smoked (median survival 22.5 versus 10.1 months,
P = .01) [47]. Skin rash is a common adverse eﬀect
observedinallclinicaltrialswithEGFR-targetingagents.The
incidence of rash was higher with erlotinib than geﬁtinib
[48] and may be due to the lower plasma concentration of
geﬁtinib compared with erlotinib when administered at the
recommended dosages of 250 and 150mg/day, respectively.
A correlation between the severity of skin rash (grade
≥2) and signiﬁcant improvement of survival was observed
in several clinical trials [49–51], and therefore, skin rash
seemed to function as a surrogate marker of eﬃcacy
[51].
Somatic mutations in the EGFR gene are most frequently
detected in NSCLC patients with a better outcome, including
adenocarcinomas histology, in particular BAC, nonsmokers,
females, and Asian ethnicity [37, 52, 53]. The most common
m u t a t i o n so fE G F Ra r ei naf r a m ed e l e t i o ni ne x o n1 9
(45%–50% of all somatic EGFR mutations) and a missense
mutation leading to leucine to arginine substitution at
codon 858 (L858R) in exon 21 (35%–45% of mutations)
[54]. Emerging data suggest that patients with NSCLC and
EGFR exon 19 deletion have a longer survival following
treatment with geﬁtinib or erlotinib compared with those
with L858R mutation [55–57]. Recently, IPASS study showed
that, in the subgroup of 261 patients who were positive for
the EGFR mutation, PFS was signiﬁcantly longer among
those receiving geﬁtinib that than among those receiving
carboplatin-paclitaxel as ﬁrst-line treatment (P<. 001) [37].
Several retrospective analyses of clinical trials have failed
to demonstrate the correlation between EGFR IHC status
and response, TTP and OS in NSCLC patients treated with
geﬁtinib or erlotinib [58–62]. Conversely, in other clinical
trials, it has been shown that high levels of EGFR protein
expression are associated with response and improvement of
survival [63–66]. Of note, EGFR FISH-positive status was
signiﬁcantly associated with certain clinical and biological
characteristics predictive for TKI sensitivity, such as female
sex, never-smoking history, and the presence of EGFR
mutations [25]. However, the most predictive marker of
response remains EGFR mutation/deletion status in the
kinase domain.
In approximately 15%–30% of lung adenocarcinomas,
activating mutations in the RAS family member were found.
This more commonly occurs in patients with smoking
history and these mutations are most frequently recorded
in codons 12 and 13 in exon 2 of the K-RAS gene [67–
69]. The role of K-RAS mutation in NSCLC patients is still
controversy, but it seems associated with a worse outcome
and a shorter survival [70].
5. Discussion
Treatment of elderly patients who have NSCLC remains a
challenge. Older adults represent a heterogenous population,
despite similar chronologic age. Individualizing treatment
decision-making based on careful patient assessment is
currently an active area of research in geriatric oncology
and will hopefully lead to improved treatment outcomes
for older adults. These patients have more comorbidities
and tend to be more intolerant of toxic medical treatment
than their younger counterparts [71]. A comprehensive
geriatric assessment (CGA), which has proven to provide
more indications compared with the performance status
assessment alone, ought to be carried out. The CGA
should include evaluation of comorbidities, socioeconomic
issues, nutritional status, polypharmacy, functional depen-
dence, emotional and cognitive conditions, an estimate of
life expectancy, and recognition of frailty. Nevertheless, a
CGA may be too lengthy in busy clinical practice; so,
validated and shorter screening instruments are needed.
The Cardiovascular Health Study divided elderly patients
into three groups (ﬁt, prefrail, frail) according to ﬁve
items (unintentional weight loss, self-reported exhaustion,
weakness, walking speed, and level of physical activity) and
hasgainedparticularprominencebecauseitiswellcorrelated
with mortality and risk of functional dependence [72, 73].
However, actually CGA remains the best option to decide on
the best-suited treatment modality for a particular geriatric
patient. Based on prospective trials for unselected elderly
advanced NSCLC, single-agent chemotherapy with third-
generation agents (vinorelbine, gemcitabine, taxanes) is still
considered the recommended treatment.
Among targeted therapies, the EGFR TKIs, erlotinib and
geﬁtinib are the most promising agents and have been shown
in phase II trials to be active and well tolerated as ﬁrst-line
treatment of advanced NSCLC in the elderly. In responders
to EGFR TKIs, the symptom relief was dramatically obtained
also in PS ≥ 2 patients [74–76]. Of note, most patients at
the time of recurrence of NSCLC have suﬀered some types
of toxicity from previous chemotherapy or comorbidities
such as chronic renal failure, contraindicating any further
chemotherapy. In a Gridelli et al. report, erlotinib at full
dosage was administered to three advanced NSCLC patients
unsuitableforchemotherapybecauseofchronicrenalfailure.
Further renal function was not impaired by therapy with
erlotinib, and no severe toxicity was recorded. Erlotinib
is metabolized in the liver, mainly by the cytochrome p-
450 isoenzyme CYP 3A4. Erlotinib and its metabolites are
excreted predominantly via feces, with renal eliminationCurrent Gerontology and Geriatrics Research 5
of drug and metabolites accounting for less than 9% of
the administered dose [77]. With interest are awaited the
results of the GEST phase II study, where elderly patients
with untreated advanced NSCLC were randomized to receive
sorafenib plus gemcitabine or sorafenib plus erlotinib [78].
Another study currently ongoing is the ZELIG phase II
randomized study with vandetanib plus gemcitabine versus
gemcitabine alone in the same subset of elderly patients.
Finally, elderly patients with advanced NSCLC and carri-
ers of an EGFR mutation may be considered for geﬁtinib or
erlotinib as ﬁrst-line treatment. However, further speciﬁcally
designed phase III randomized trials are needed to optimize
medicaltreatmentofelderlypatientswithadvancedNSCLC.
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